Skip to main content
. Author manuscript; available in PMC: 2017 Aug 31.
Published in final edited form as: Adv Drug Deliv Rev. 2017 Jun 10;113:177–200. doi: 10.1016/j.addr.2017.06.002

Figure 8.

Figure 8

Survival of mice with brain metastases from primary HER2+ breast, triple negative breast cancer (TNBC) and lung cancers, which are positive for EGFR+, after treatment with tumor-targeted therapeutic polymers inhibiting the expression of HER2 or EGFR. Treatment was performed after MRI-based differential diagnoses of brain lesions made with nanoimaging agents (see Fig. 6). Reproduced from [14].